PO-0799: Normal brain, neural stem cells and glioblastoma responses to FLASH radiotherapy  by Montay - Gruel, P. et al.
S400                                                                                                                                         3rd ESTRO Forum 2015 
 
tumor volume reduction than meningiomas that were 3 (8.94% 
vs. 7.59% per year). These results suggest that a notable 
tumor volume reduction is predicted within 3 to 4 years after 
irradiation, and thereafter, the tumor volume decreases at a 
slower rate for more than 10 years. 
Conclusions: The quantitative volumetric analysis of the 
pattern of tumor volume reduction in response to irradiation 
gives an insight into the radiobiological nature of intracranial 
meningiomas after conventionally fractionated radiation 
therapy. 
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Purpose/Objective: To evaluate the safety and efficacy of 
postoperative hyperfractionated concomitant boost proton 
radiotherapy for supratentorial glioblastoma multiforme 
(GBM). 
Materials and Methods: Forty-six patients with supratentorial 
GBM were treated by high dose (96.6 GyE) photon and proton 
radiotherapy. There were 24 males and 22 females, and the 
median age was 58 years old (range: 24 - 76). The KPS were 
50, 60, 70, 80, 90, and 100 % in 1,4,10,12,11, and 8 patients, 
respectively. The median MIB-1 index was 30.8 (range:5.1-
70). The gross total resection, subtotal resection, and partial 
resection were performed for 2, 29, and 15 patients, 
respectively. Photon beam were delivered to the T(2)-
weighted high area on magnetic resonance imaging (MRI) in 
the morning (50.4 Gy in 28 fractions). More than 6 hours 
later, proton beams were delivered to the enhanced area 
plus a 10-mm margin in the first half of the protocol (23.1 
GyE in 14 fractions) and to the enhanced volume in the latter 
half (23.1 GyE in 14 fraction). Concurrent chemotherapy with 
nimustine hydrochloride (80 mg/m2) during first and fourth 
weeks or daily temozolomide (75mg/m2) was administrated 
in 23 and 23 patients, respectively. 
Results: The overall survival rates after 1 and 2 years were 
80.4% and 44.6%, respectively. The median survival period 
was 21.1 months (95% CI: 13.0-29.1). The 1- and 2-year 
progression-free survival rates were 34.8% and 8.7%, 
respectively. There was no significant survival difference 
between nimustine hydrochloride and temozolomide groups 
(p=0.33). Acute toxicity was mainly hematologic and was 
controllable. Late radiation necrosis and 
leukoencephalopathy were seen in 11 and 2 patients, 
respectively, but all patients with radiation necrosis were 
controlled by necrotomy and medical therapy including 
bevacizumab administration. 
Conclusions: Hyperfractionated concomitant boost proton 
radiotherapy (96.6 GyE in 56 fractions) with nimustine 
hydrochloride or temozolomide for GBM was tolerable and 
beneficial for patients with supratentorial GBM. 
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Purpose/Objective: Bevacizumab has been extensively 
studied in recurrent high-grade glioma patients as first and 
second-line therapy. To date, there is a limited number of 
reports on its epidemiological use in an unselected patient 
cohort. Therefore, we report on our experience on a large 
number of patients treated at our institution. 
Materials and Methods: After receiving standard 
radiotherapy (with or without TMZ) patients with recurrent 
malignant glioma were treated with bevacizumab (10mg/kg 
intravenously, q2w), either as mono/combination therapy 
(27.2%), upfront (12%) or in combination to re-irradiation, 
with (22.4%) or without maintenance therapy (38.4%). Median 
prescribed radiation dose during re-treatment was 36Gy, 
conventionally fractionated. 
Results: 125 patients were included in this retrospective 
analysis with proven high-grade glioma. Median age was 50 
years and median KPS at re-treatment 80. Median number of 
bevacizumab cycles preceding progression was three, with 
median four cumulative cycles. 
Median follow-up after initiation of bevacizumab treatment 
was 37 months and median overall survival since first 
diagnosis 29 months (WHO grades III + IV). Median post-
recurrence survival was 9 months, median post-recurrence 
PFS 5 months (PFS-6 36.5%). 
Univariate testing revealed that sex, WHO grade, time 
interval from initial diagnosis, MGMT methylation, IDH 
mutation, combination with irinotecan and age had no 
significant influence on neither PRS nor PR-PFS. Significant 
factors according to PRS/PR-PFS were a KPS < 70 (PR-PFS 
median 3 vs. 6 months, p=0.02; PRS median 5 vs. 10 months, 
p=0.007), a larger number of bevacizumab cycles and the 
respective treatment group (most favorable: re-RT + 
bevacizumab + maintenance therapy). 
Conclusions: Bevacizumab appears to be a valuable agent in 
recurrent malignant glioma therapy. Activity of monotherapy 
was seen, especially in combination with reirradiation. KPS 
was the most important predictor for both PRS and PR-PFS. 
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Purpose/Objective: Glioblastoma (GBM) is a very aggressive 
and radioresistant tumor associated with bad prognosis. 
Current trends in GBM treatments are based on a 
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combination of surgery, chemotherapy and radiation therapy. 
The side effects still are the main limitation of brain tumors’ 
treatment by radiotherapy and do not allow the dose 
escalation needed to treat these highly radio-resistant 
tumors. In this research program, we propose a new FLASH 
radiotherapy modality based on the dose delivery at ultrahigh 
dose-rate (above 50Gy/s), which has shown an important 
differential effect with the protection of normal tissues and 
stem cells and an efficient antitumor effect (Favaudon et al. 
2014).  
Materials and Methods: Two LINACs prototypes are used: a 
4.5 MeV (Institut Curie) and a 6 MeV (CHUV) to investigate 
the normal brain response and the antitumor effect of FLASH 
irradiation on GBM models in a preclinical study with an 
ultimate aim to apply this treatment to GBM bearing 
patients. For the studies on normal brain, C57Bl6/J mice 
were irradiated at the whole brain level at single doses 
ranging from 10 to 80 Gy FLASH (>50Gy/s), at 10 Gy CONV 
(0.04Gy/s) and sham irradiated (6 mice in each group). Two 
months post-irradiation, cognitive tests were performed on 
mice to evaluate the mid-term memory with a novel object 
recognition test (Acharya et al. 2009) and brains were 
sampled. Two hours before the sampling, mice were injected 
with BrdU, brains were collected and immunohistochemistry 
and NSCs quantification were performed on brain sections. To 
evaluate the FLASH antitumor effect, human GBM were 
engrafted to nude mice. The tumors were locally irradiated 
at 10 Gy CONV, from 10 to 30 Gy FLASH and sham irradiated. 
Tumor growth delay was measured.  
Results: Our preliminary results show that 50Gy FLASH 
irradiation on the whole brain does not induce any 
macroscopic toxicity nor mice’s health alteration whereas a 
pan-encephalic irradiation of 10Gy CONV is the maximum 
tolerated dose for long term follow-up. The cognitive tests’ 
results show a drop in cognitive skills after 10Gy CONV 
irradiation whereas mid-term visual memorization is not 
significantly affected at 50Gy FLASH. In correlation, two 
months after irradiation, the quantification of NSCs shows 
their preservation in the SGZ at doses up to 20Gy FLASH 
whereas 10Gy CONV eradicates all the hippocampal NSCs at 
the same timepoint. Astrocytic toxicity has also been 
investigated and shows that 10Gy CONV irradiation induces a 
high level of gliosis and astrocytes’ remodeling whereas few 
gliosis and astrocytes’ modifications are observed after 50Gy 
FLASH. At the tumor level and at similar doses, the FLASH 
and CONV irradiations induce a similar growth retardation. 
Nevertheless, the FLASH irradiation’s innocuousness on 
normal tissue does allow a dose escalation and thus an 
enhancement of the tumor growth delay. We are currently 
escalading the dose to achieve the tumor control. 
Conclusions: Altogether these results suggest that the FLASH 
radiotherapy allows the delivery of very high doses to the 
whole brain, sparing normal tissues and NSCs and eradicating 
tumor cells. In the follow up of these preliminary 
experiments we are developing orthotopic and spontaneous 
GBM models in mice (in collaboration with K. Shchors and D. 
Hanahan, EPFL) to define the molecular basis of the FLASH 
differential effect. 
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Purpose/Objective: To evaluate clinical-radiological 
response and outcome in soft tissue sarcomas of extremities, 
in patients treated with neoadjuvant radiochemotherapy. 
Materials and Methods: 74 patients (25 females, 49 males; 
median age 53.7 years, range: 27-87), were treated with 
neoadjuvant chemotherapy (CT) and radiotherapy (RT). 
Selection criteria were diseases of large dimension or in close 
proximity of critical structures such as nerves or vessels. 
Based on RMN images, the Gross Tumor Volume (GTV), 
defined as the macroscopic volume of disease visible in the 
T1-weighted sequences, was included. MRI images were 
merged with those of TC-simulation. For CTV definition, an 
expansion of 4 cm in cranio-caudal (except where anatomical 
barriers were present) and 1 cm in anterior-posterior and 
lateral-side was given to the GTV. PTV was defined as CTV + 
1 cm isotropically. All patients underwent CT, MRI +/- PET 
before RT, at the end of RT (before surgery) and during 
follow-up (FU). 
Results: At preoperative MRI revaluation the volumetric size 
of the tumor showed an average reduction of 34% (range 
+83.0% to -88.8%). Only 24 patients (32.4%) needed an 
adjuvant RT-boost for marginal or intralesional margins. Only 
three patients had local relapse at 3-13-31 months after 
surgery and were treated with surgical resection or 
brachytherapy, with local control of the disease in the 
following radiological-clinical controls. Patients with smaller 
tumors (< median) and better clinical response (> median) 
showed a trend for improved disease free survival at 5 years 
(92.9% vs 61.8%; p=0.058). Twenty patients developed 
metastases during the FU (90% lung metastases). Two out of 
74 patients died. With a median FU of 46.4 months (range 6-
113 months) 12.8% of patients showed lymphedema, 10.8% 
had mild functional impairment and 5.4% reported reduced 
sensibility in the treated site.  
Conclusions: The preoperative approach allowed to irradiate 
smaller volumes compared to adjuvant RT and to deliver 
lower doses (50 Gy/25 fractions + 20 Gy boost only in case of 
positive margins, versus 60-66 Gy/30 fractions). Neoadjuvant 
RT produced a significant reduction of the tumor volume, 
allowing a less invasive and more conservative surgical 
approach, and high long-term local control rates. 
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